Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30375337 | 1.00 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL399841 | 0.87 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22468902 | 0.84 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3256021 | 0.84 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30349688 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL670944 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3258137 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8231467 | 0.81 | CYP19A1 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2994444 | 0.81 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL190911 | 0.81 | CA12 (0.72) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent KGaA (DE) | 2025-01-30 | — | — | US | disclosed |
| EP-4426700-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent GmbH (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-116813475-A | Halogenated synthesis method of aromatic ring compound | 北京大学 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| US-8815930-B2 | Compounds that inhibit TRPV1 and uses thereof | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-7767705-B2 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1377573-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| EP-1366048-A2 | PYRAZOLOPYRIDINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | MAXIA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002072581-A2 | PYRAZOLOPYRIADINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002048148-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | CA12 736/4885CA1 1029/4885CA2 715/4885 |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, PPARG, CPT2 | CA12 2026/4885CA1 2382/4885CA2 1897/4885 |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, UBQLN1, TTI1 | CA12 4573/4885CA1 4324/4885CA2 3851/4885 |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | CA12 4335/4885CA1 3611/4885CA2 1441/4885 |
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | TRPV1, TRPV3, TRPA1 | CA12 4314/4885CA1 2642/4885CA2 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.